Recently, the lung cancer compact panel (LCCP), which is an amplicon-based high-sensitivity next-generation sequencing panel test capable of measuring eight druggable genes, was approved as a companion diagnostic for EGFR mutations, ALK fusions, ROS1 fusions, and MET Ex.14 skipping mutations in November 2022 in Japan. Here, ALK is linked to lung cancer.